Table 1

Characteristics of the sustained period of “getting to zero” VAP prevention program in the ICU
2009 2010
Patient-days (total) 10,889 11,095
Number of patients 2,705 2,717
Age, mean ± SD(in years) 67±19 66±18
Male, n (%) 1,571 (58.1%) 1,587 (58.4%)
APACHE, mean ± SD 18±6 18±7
Ventilator-days (total) 3,009 3,043
Ventilator utilization ratio 0.28 0.27
MV days – median(IQR) 4 (1–22) 3.7 (1–23)
Ventilator-free days 7,880 8,052
ICU LOS days –mean ± SD 3.9±0.4 4.0±0.3
Compliance with process measures,n (%)
HOB observations 2362/2396 (98.6%) 2260/2486 (90.9%)
Daily “sedation interruptions” 2358/2396 (98.4%) 2273/2486 (91.4%)
Gastric prophylaxis 2393/2396 (99.9%) 2276/2486 (91.5%)
DVT/PE prevention 2363/2396 (98.6%) 2266/2486 (91.1%)
Ventilator circuits without changes 610/611 (99.8%) 387/390 (99.2%)
HMEs changed 584/611 (95.5%) 368/390 (94.3%)
Ventilator-circuit-tubing condensate 564/611 (92.3%) 360/390 (92.3%)
CASS endotracheal tube -n 342 311
Number of VAPs 4 6
Number of VATs 3 6
VAP rate per 1,000ventilator-days 1.3 2.0
VAT rate per 1,000ventilator-days 1.0 2.0
In-hospital mortality in VAPpatients, n (%) 4/4 (100) 5/6 (83)
In-hospital mortality in ICUpatients, n 196 220
In-hospital mortality in ICUpatients per 10,000 patientdays 180 198

CASS Continuous Aspiration of Subglottic Secretions.

DVT/PE Deep Venous Thrombosis/Pulmonary Embolism.

ICU LOS Intensive Care – Length of Stay.

HMEs Heat-and-Moisture Exchanges.

HOB Head of the Bed.

MV Mechanical Ventilation.

SD Standard Deviation.

VAP Ventilator Associated Pneumonia.

VAT Ventilator Associated Tracheobronchitis.

Caserta et al.

Caserta et al. BMC Infectious Diseases 2012 12:234   doi:10.1186/1471-2334-12-234

Open Data